Related Experiment Video
Updated: Jan 31, 2026

High Throughput Microinjections of Sea Urchin Zygotes
Published on: January 21, 2014
Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models
Tamara Babic1, Jelena Dinic2, Sonja Stojkovic Buric2
11 Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Vojvode Stepe 444a, 11010, Belgrade , Serbia.
Abstract:
Cancer drug resistance and poor selectivity towards cancer cells demand the constant search for new therapeutics. PI3K-Akt-mTOR and RAS-MAPK-ERK signaling pathways are key mechanisms involved in cell survival, proliferation, differentiation, and metabolism and their deregulation in cancer can promote development of therapy resistance. We investigated the effects of targeted inhibitors (wortmannin, GSK690693, AZD2014 and tipifarnib) towards these two pathways on early zebrafish and sea urchin development to assess their toxicity in normal, fast proliferating cells. PI3K inhibitor wortmannin and RAS inhibitor tipifarnib displayed highest toxicity while GSK690693, a pan-Akt kinase inhibitor, exhibited a less significant impact on embryo survival and development. Moreover, inhibition of the upstream part of the PI3K-Akt-mTOR pathway (wortmannin/GSK690693 co-treatment) produced a synergistic effect and impacted zebrafish embryo survival and development at much lower concentrations. Dual mTORC1/mTORC2 inhibitor AZD2014 showed no considerable effects on embryonic cells of zebrafish in concentrations substantially toxic in cancer cells. AZD2014 also caused the least prominent effects on sea urchin embryo development compared to other inhibitors. Significant toxicity of AZD2014 in human cancer cells, its capacity to sensitize resistant cancers, lower antiproliferative activity against human normal cell lines and fast proliferating embryonic cells could make this agent a promising candidate for anticancer therapy.
Insights
Targeted cancer therapy inhibitors showed varying toxicity in early development. AZD2014, a dual mTOR inhibitor, demonstrated significant promise for anticancer therapy due to its selective toxicity.
Area of Science:
- Pharmacology
- Developmental Biology
- Cancer Research
Background:
- Cancer drug resistance and poor selectivity necessitate novel therapeutics.
- PI3K-Akt-mTOR and RAS-MAPK-ERK pathways are crucial in cell functions and cancer development.
- Deregulation of these pathways contributes to therapy resistance.
Purpose of the Study:
- To evaluate the toxicity of targeted pathway inhibitors on early zebrafish and sea urchin development.
- To assess the potential of these inhibitors as anticancer agents by examining their effects on normal, fast-proliferating cells.
Main Methods:
- Investigated effects of wortmannin, GSK690693, AZD2014, and tipifarnib on early development.
- Assessed toxicity and impact on embryo survival and development in zebrafish and sea urchins.
- Compared inhibitor effects on embryonic cells versus cancer cells.
Main Results:
- Wortmannin (PI3K inhibitor) and tipifarnib (RAS inhibitor) showed highest toxicity.
- GSK690693 (pan-Akt inhibitor) had a less significant impact.
- Combined PI3K-Akt-mTOR inhibition (wortmannin/GSK690693) showed synergistic toxicity.
- AZD2014 (dual mTOR inhibitor) exhibited low toxicity in embryonic models but high toxicity in cancer cells, with minimal effects on normal cells.
Conclusions:
- AZD2014 displays selective toxicity towards cancer cells, making it a promising candidate for anticancer therapy.
- Its ability to sensitize resistant cancers and low antiproliferative activity against normal cells supports its therapeutic potential.
- Further investigation into AZD2014 is warranted for its development as a novel cancer treatment.
Related Concept Videos
Comparative Excretory Systems
Effect of Sea Water on Concrete
Concrete in areas between tide marks,...
Self-Evaluation Maintenance Model
Keystone Species
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Therapeutic Index

